Personalis (PSNL)
(Delayed Data from NSDQ)
$5.16 USD
+0.50 (10.73%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $5.14 -0.02 (-0.39%) 5:46 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PSNL 5.16 +0.50(10.73%)
Will PSNL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PSNL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PSNL
Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
PSNL: What are Zacks experts saying now?
Zacks Private Portfolio Services
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
Other News for PSNL
Small-caps get a lift after Fed's jumbo rate cut: See top 20 names in SA Quant ratings
Small-caps get a lift after Fed's jumbo rate cut; see top 20 names in SA Quant ratings
Small-caps get a lift after Fed's jumbo rate cut; see top 20 names per SA Quant ratings
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal? MRD Test
Small-cap stocks have climbed recently. Here are the ones most poised for further upside